145 related articles for article (PubMed ID: 37940542)
1. A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report.
Harada S; Imakura T; Sato S; Nokihara H; Nishioka Y
J Med Invest; 2023; 70(3.4):516-520. PubMed ID: 37940542
[TBL] [Abstract][Full Text] [Related]
2. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
3. Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia.
Yılmaz A; Mirili C; Bilici M; Tekin SB
J Oncol Pharm Pract; 2020 Oct; 26(7):1791-1794. PubMed ID: 32237958
[TBL] [Abstract][Full Text] [Related]
4. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
Fu S; Wang T; Xu F
J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Ito M; Kanda S; Yoshida T; Okuma Y; Jo H; Fukuhara S; Maeshima AM; Ohe Y
Lung Cancer; 2020 Aug; 146():362-365. PubMed ID: 32505447
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
7. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
[TBL] [Abstract][Full Text] [Related]
8. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Baba Y; Sakai H; Kabasawa N; Harada H
Intern Med; 2022 Jun; 61(12):1891-1895. PubMed ID: 35400701
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
Gardellini A; Guidotti F; Feltri M; Zancanella M; Maino E; Ambrosiani L; Turrini M
Blood Cells Mol Dis; 2021 Dec; 92():102620. PubMed ID: 34715450
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
15. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
16. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
17. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome.
Xu L; Zhang Y; Lin N; Song X; Dai Q
Sci Prog; 2022; 105(2):368504221102786. PubMed ID: 35603866
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
